Skip Navigation

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive Ph+ Acute Lymphoblastic Leukemia ALL Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation

Brief Summary


Study Type:

I/II Identifier:

Study #:
CMH - AALL1922

Start Date:
Oct 25, 2021

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT04501614

View Complete Trial Details & Eligibility at